Journal of Autism and Developmental Disorders

, Volume 27, Issue 4, pp 467–478 | Cite as

High-Dose Pyridoxine and Magnesium Administration in Children with Autistic Disorder: An Absence of Salutary Effects in a Double-Blind, Placebo-Controlled Study

  • Robert L. Findling
  • Kathleen Maxwell
  • Lynette Scotese-Wojtila
  • Jie Huang
  • Toyoko Yamashita
  • Max Wiznitzer


Several reports have described salutary effects such as decreased physical aggression and improved social responsiveness being associated with the administration of high doses of pyridoxine and magnesium (HDPM) in open-labeled and controlled studies of patients with autism. Despite this fact, this intervention remains controversial. A 10-week double-blind, placebo-controlled trial was undertaken to examine both the efficacy and safety of HDPM in autism. Twelve patients were enrolled, and 10 patients (mean age 6 years 3 months) were able to complete the study. HDPM at an average dose of 638.9 mg of pyridoxine and 216.3 mg of magnesium oxide was ineffective in ameliorating autistic behaviors as assessed by the Children's Psychiatric Rating Scale (CPRS), the Clinical Global Impression Scale, and the NIMH Global Obsessive Compulsive Scale. Furthermore, no clinically significant side effects were noted during HDPM administration. A trend for a transient change on the CPRS was found that was possibly due to a placebo response. This study raises doubts about the clinical effectiveness of HDPM in autistic disorder.


Oxide Placebo Magnesium Pyridoxine Physical Aggression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aman, M. G., Van Bourgondien, M. E., Wolford, P. L., & Sarphare, G. (1995). Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1672–1681.Google Scholar
  2. American Academy of Pediatrics, Committee on Nutrition. (1976). Megavitamin therapy for childhood psychoses and learning disabilities. Pediatrics, 58, 910–912.Google Scholar
  3. American Psychiatric Association. (1987). Diagnostic and statistical manual of mental disorders (3rd ed., rev.). Washington DC: Author.Google Scholar
  4. Anderson, L. T., Campbell, M., Grega, D. M., Perry, R., Small, A. M., & Green, W. H. (1984). Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. American Journal of Psychiatry, 141, 1195–1202.Google Scholar
  5. Campbell, M., & Palij, M. (1985). Behavioral and cognitive measures used in psychopharmacologic studies of infantile autism. Psychopharmacology Bulletin, 21, 1047–1053.Google Scholar
  6. Campbell, M., Anderson, L. T., Small, A. M., Adams, P., Gonzalez, N. M., & Ernst, M. (1993). Naltrexone in autistic children: Behavioral symptoms and attentional learning. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 1283–1291.Google Scholar
  7. Coleman, M., Steinberg, G., Tippett, J., Bhagavan, H. N., Coursin, D. B., Gross, M., Lewis, C., & DeVeau, L. (1979). A preliminary study of the effect of pyridoxine administration in a subgroup of hyperkinetic children: A double-blind crossover comparison with methylphenidate Biological Psychiatry, 14, 741–751.Google Scholar
  8. DeVeaugh-Geiss, J., Moroz, G., Biederman, J., Cantwell, D., Fontaine, R., Greist, J. H., Reichler, R., Katz, R., & Landau, P (1992). Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder—a multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 45–49.Google Scholar
  9. DiLalla, D. L., & Rogers, S. J. (1994). Domains of the Childhood Autism Rating Scale: Relevance for diagnosis and treatment. Journal of Autism and Developmental Disorders, 24, 115–128.Google Scholar
  10. Dolske, M. C., Spollen, J., McKay, S., Lancashire, E., & Tolbert, L. (1993). A preliminary trial of ascorbic acid as supplemental therapy for autism. Progress in Neuropsychopharmacology and Biological Psychiatry, 17, 765–774.Google Scholar
  11. Eisenberg, D. M., Kessler, R. C., Foster, C., Norlock, F. E., Calkins, D. R., & Delbanco, T. L. (1993). Unconventional medicine in the United States. New England Journal of Medicine, 328, 246–252.Google Scholar
  12. Ernst, M., Devi, L., Silva, R. R., Gonzalez, N. M., Small, A. M., Malone, R. P, & Campbell, M. (1993). Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children. Psychopharmacology Bulletin, 29, 221–227.Google Scholar
  13. Frankhauser, M. P., Karumanchi, V. C., German, M. L., Yates, A., & Karumanchi, S. D. (1992). A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Journal of Clinical Psychiatry, 53, 77–82.Google Scholar
  14. Gillberg, C., Wahlstrom, J., Johansson, R., Tornblom, M., Albertson-Wikland, K. (1986). Folic acid as an adjunct in the treatment of children with the autism fragile-X syndrome (AFRAX). Developmental Medicine & Child Neurology, 28, 624–627.Google Scholar
  15. Gonzalez, N. M., Campbell, M., Small, A. M., Shay, J., Bluhm, L. D., Adams, P. B., & Foltz, R. L. (1994). Naltrexone plasma levels, clinical response and effect on weight in autistic children. Psychopharmacology Bulletin, 30, 203–208.Google Scholar
  16. Gordon, C. T., Rapoport, J. L., Hamburger, S. D., State, R. C., & Mannheim, G. B. (1992). Differential response of seven subjects with autistic disorder to clomipramine and desipramine. American Journal of Psychiatry, 149, 363–366.Google Scholar
  17. Gordon, C. T., State, R. C, Nelson, J. E., Hamburger, S. D., & Rapoport, J. L. (1993). A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Archives of General Psychiatry, 50, 441–447.Google Scholar
  18. Goyette, C. H., Conners, C. K., & Ulrich, R. F. (1978). Normative data on revised Conners parent and teacher rating scales. Journal of Abnormal Child Psychology, 6, 221–236.Google Scholar
  19. Hanning, R. M., & Zlotkin, S. H. (1985). Unconventional eating practices and their health implications. Pediatric Clinics of North America, 32, 429–445.Google Scholar
  20. Insel, T. R., Murphy, D. L., Cohen, R. M., Alterman, I., Kilts, C., & Linnoila, M. (1983). Obsessive-compulsive disorder: A double-blind trial of clomipramine and clorgyline. Archives of General Psychiatry, 40, 605–612.Google Scholar
  21. Jakobs, C., Jaeken, J., & Gibson, K. M. (1993). Inherited disorders of GABA metabolish. Journal of Inherited Metabolic Disease, 16, 704–715.Google Scholar
  22. Jaselskis, C. A., Cook, E. H., Jr., Fletcher, K. E., & Leventhal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12, 322–327.Google Scholar
  23. Kolmen, B. K., Feldman, H. M., Handen, B. L., & Janosky, J. E. (1995). Naltrexone in young autistic children; A double-blind, placebo-controlled crossover study. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 223–231.Google Scholar
  24. Lelord, G., Muh, J. P., Barthelemy, C., Martineau, J., Garreau, B., & Callaway, E. (1981). Effects of pyridoxine and magnesium on autistic symptoms-initial observations. Journal of Autism and Developmental Disorders, 11, 219–230.Google Scholar
  25. Leventhal, B. L, Cook, E. H., Jr., Morford, M., Ravitz, A. J., Heller, W., & Freedman, D. X. (1993). Clinical and neurochemical effects of fenfluramine in children with autism. Journal of Neuropsychiatry and Clinical Neurosciences, 5, 307–315.Google Scholar
  26. Martineau, J., Barthelemy, C., Gareau, B., & Lelord, G. (1985). Vitamin B6, magnesium, and combined B6-Mg: Therapeutic effects in childhood autism. Biological Psychiatry, 20, 467–478.Google Scholar
  27. Martineau, J., Barthelemy, C., & Lelord, G. (1986). Long-term effects of combined vitamin B6-magnesium administration in an autistic child. Biological Psychiatry, 21, 511–518.Google Scholar
  28. Martineau, J., Barthelemy, C., Cheliakine, C., & Lelord, G. (1988). Brief report: An open middle-term study of combined vitamin B6-magnesium in a subgroup of autistic children selected on their sensitivity to this treatment. Journal of Autism and Developmental Disorders, 18, 435–447.Google Scholar
  29. McLachlan, R. S., & Brown, W. F. (1995). Pyridoxine dependent epilepsy with iatrogenic sensory neuronopathy. Canadian Journal of Neurologic Sciences, 22, 50–51.Google Scholar
  30. Menage, P., Thibault, G., Barthélèmy, C., Lelord, G., & Bardos, P. (1992). CD4+CD45RA+T lymphocyte deficiency in autistic children: Effect of a pyridoxine-magnesium treatment. Brain Dysfunction, 5, 326–333.Google Scholar
  31. National Institute of Mental Health. (1985). Clinical Global Impression Scale. Psychopharmacology Bulletin, 21, 839–843.Google Scholar
  32. Overall, J. E., & Campbell, M. (1988). Behavioral assessment of psychopathology in children: Infantile autism. Journal of Clinical sychology, 44, 708–716.Google Scholar
  33. Pauling, L. (1974). On the orthomolecular environment of the mind: Orthomolecular theory. American Journal of Psychiatry, 131, 1251–1257.Google Scholar
  34. Pfeiffer, S. I., Norton, J., Nelson, L., & Shott, S. (1995). Efficacy of vitamin B6 and magnesium in the treatment of autism: A methodology review and summary of outcomes. Journal of Autism and Developmental Disorders, 25, 481–493.Google Scholar
  35. Quintana, H., Birmaher, B., Stedge, D., Lennon, S., Freed, J., Bridge, J., & Greenhill, L. (1995). Use of methylphenidate in the treatment of children with autistic disorder. Journal of Autism and Developmental Disorders, 25, 283–294.Google Scholar
  36. Rimland, B. (1988). Controversies in the treatment of autistic children: Vitamin and drug therapy. Journal of Child Neurology, 3(Suppl), S68–S72.Google Scholar
  37. Rimland, B., Callaway, E., & Dreyfus, P. (1978). The effect of high doses of vitamin B6 on autistic children: A double-blind crossover study. American Journal of Psychiatry, 135, 472–475.Google Scholar
  38. Schaumberg, H., Kaplan, J., Windebank, A., Vick, N., Rasmus, S., Pleasure, D., & Brown, M. J. (1983). Sensory neuropathy from pyridoxine abuse: A new megavitamin syndrome. New England Journal of Medicine, 309, 445–448.Google Scholar
  39. Schopler, E., Reichler, R., DeVellis, R., & Daly, K. (1980). Toward objective classification of childhood autism: Childhood autism rating scale (CARS). Journal of Autism and Developmental Disorders, 10, 91–103.Google Scholar
  40. Schulz, K. F., Chalmers, I., Hayes, R. J., & Altman, D. G. (1995). Empiric evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association, 273, 408–412.Google Scholar
  41. Spigelblatt, L., Laine-Ammara, G., Pless, B., & Guyver, A. (1994). The use of alternative medicine by children. Pediatrics, 94, 811–814.Google Scholar
  42. Tolbert, L., Haigler, T., Waits, M. M., & Dennis, T. (1993). Brief report: Lack of response in an autistic population to a low dose clinical trial of pyridoxine and magnesium. Journal of Autism and Developmental Disorders, 23, 193–199.Google Scholar
  43. Willemsen-Swinkels, S. H. N., Buitelaar, J. K., Nijhof, G. J., & van Engeland, H. (1995). Failure of naltrexone hydrochloride to reduce self-injuries and autistic behavior in mentally retarded adults: Double-blind placebo-controlled studies. Archives of General Psychiatry, 52, 766–773.Google Scholar
  44. Wolraich, M. L., Wilson, D. B., & White, J. W. (1995). The effect of sugar on behavior or cognition in children: A meta-analysis. Journal of the American Medical Association, 274, 1617–1621.Google Scholar

Copyright information

© Plenum Publishing Corporation 1997

Authors and Affiliations

  • Robert L. Findling
    • 1
  • Kathleen Maxwell
    • 2
  • Lynette Scotese-Wojtila
    • 2
  • Jie Huang
    • 3
  • Toyoko Yamashita
    • 3
  • Max Wiznitzer
    • 1
  1. 1.Case Western Reserve University and University Hospitals of ClevelandUSA
  2. 2.University Hospitals of ClevelandUSA
  3. 3.Case Western Reserve UniversityUSA

Personalised recommendations